Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?

Diabetes Care

Volumn 28, Issue 1, 2005, Pages 101-107

  Drexel, Heinz ^a,b,d   Aczel, Stefan ^a,b   Marte, Thomas ^a   Benzer, Werner ^b   Langer, Peter ^a   Moll, Willi ^c   Saely, Christoph H ^a,b  

^a Vorarlberg Inst Vasc Invest T   (Austria)

^b ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^c Institute for Clinical Chemistry   (Austria)

^d VIVIT   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FACTORIAL ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; GLUCOSE INTOLERANCE; HUMANS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 11844278418     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.1.101     Document Type: Article

References (37)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035-2038, 1979
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
4. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
5. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
6. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316:823-828, 1998
7. Betteridge DJ: Diabetic dyslipidaemia. Eur J Clin Invest 29 (Suppl. 2): 12-16, 1999
8. Howard BV, Knowler WC, Vasquez B, Kennedy AL, Pettitt DJ, Bennett PH: Plasma and lipoprotein cholesterol and triglyceride in the Pima Indian population: comparison of diabetics and nondiabetics. Arteriosclerosis 4:462-471, 1984
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
10. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749, 2003
11. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
12. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial: the Care Investigators. Circulation 98:2513-2519, 1998
13. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162:2597-2604, 2002
14. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15:820-825, 1992
15. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21-27, 2000
16. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
17. Drexel H, Amann FW, Rentsch K, Neuenschwander C, Luethy A, Khan SI, Follath F: Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 70:436-440, 1992
18. Drexel H, Amann FW, Beran J, Rentsch K, Candinas R, Muntwyler J, Luethy A, Gasser T, Follath F: Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 90:2230-2235, 1994
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
20. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monaum T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23:57-63, 2000
21. Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201-229, 2002
22. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvmen H, Shepherd J, Taskinen MR: Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454-462, 1997
23. Taskinen MR: Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 109 (Suppl. 2):S180-S188, 2001
24. Lamarche B, Rashid S, Lewis GF: HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 286:145-161, 1999
25. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003
26. Alexander CM, Landsman PB, Teutsch SM: Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 86:897-902, 2000
27. Piperi C, Kalofoutis C, Papaevaggeliou D, Papapanagiotou A, Lekakis J, Kalofoutis A: The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease. Clin Bwchem 37:377-381, 2004
28. French JK, Elliott JM, Williams BF, Nixon DJ, Denton MA, White HD: Association of angiographically detected coronary artery disease with low levels of high-density lipoprotein cholesterol and systemic hypertension. Am J Cardiol 71:505-510, 1993
29. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJ: Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 309:385-389, 1983
30. Syvanne M, Pajunen P, Kahri J, Lahdenpera S, Ehnholm C, Nieminen MS, Taskinen MR: Determinants of the severity and extent of coronary artery disease in patients with type-2 diabetes and in nondiabetic subjects. Coron Artery Dis 12:99-106, 2001
31. Laakso M, Lehto S, Penttila I, Pyorala K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88:1421-1430, 1993
32. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32:300-304, 1989
33. Salles GF, Bloch KV, Cardoso CR: Mortality and predictors of mortality in a cohort of Brazilian type 2 diabetic patients. Diabetes Care 27:1299-1305, 2004
34. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, Cowan LD, Gray RS, Welty TK, Go OT, Howard WJ: LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart Study. Arterioscler Thromb Vasc Biol 20:830-835, 2000
35. Nishtar S, Wierzbicki AS, Lumb PJ, Lambert-Hammill M, Turner CN, Crook MA, Mattu MA, Shahab S, Badar A, Ehsan A, Marber MS, Gill J: Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Curr Med Res Opin 20:55-62, 2004
36. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Manno EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001
37. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350:1505-1515, 2004